Dr. Gasparetto on Selinexor and Daratumumab Combination in Multiple Myeloma
Cristina Gasparetto, MD
Cristina Gasparetto, MD, assistant professor of medicine, member of the Duke Cancer Institute, discusses a phase Ib study of the combination of selinexor and daratumumab (Darzalex) in patients with relapsed/refractory multiple myeloma.
There are preliminary data demonstrating that selinexor resensitizes the myeloma cells to daratumumab, Gasparetto says.
This study was attempting to determine the dose of the combination. In the first cohort selinexor and daratumumab was given 60 mg/kg twice a week, explains Gasparetto.